

June 10, 2020

To,

**BSE Limited**

Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400 001

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

Scrip code: 512529

Symbol: SEQUENT

**Subject: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transactions on a consolidated basis for the year ended March 31, 2020, in the format specified in the relevant Accounting Standards.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



**Krunal Shah**  
**Company Secretary & Compliance Officer**



Encl.: As above

**SeQuent Scientific Limited**

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area,  
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

**Disclosure of related party transactions on consolidated basis**

*In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018*

**A List of related parties**

**a) Key management personnel**

- Mr. Manish Gupta, Chief Executive Officer & Managing Director
- Mr. Sharat Narasapur, Joint Managing Director
- Mr. Tushar Mistry, Chief Financial Officer
- Mr. Krupesh Mehta, Company Secretary (Till 29 June 2019)
- Mr. Krunal Shah, Company Secretary (From 13 November 2019)
- Mr. K E C Rajakumar, Non-Executive Director
- Dr. S Devendra, Non-Executive Director
- Dr. Gopakumar G. Nair, Chairman and Independent Director
- Dr. Kausalya Santhanam, Independent Director
- Mr. Narendra Mairpady, Independent Director

**Relative of KMP**

Mrs. Anita M Gupta (wife of Mr. Manish Gupta)

**b) Enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries**

- Strides Pharma Sciences Limited (formerly known as Strides Shasun Limited)
- Strides Emerging Markets Limited
- Agnus Capital LLP
- Atma Projects
- Naari Pharma Private Limited
- Tenshi Kaizen Private Limited
- Stelis Biopharma Private Limited
- Solara Active Pharma Sciences Limited
- Sequent Penems Private Limited



*[Handwritten signature]*  
 Company Secretary

*[Handwritten signature]*  
 Chief Financial Officer



**B Transactions during the period 01 October 2019 to 31 March 2020**

(₹ in Million)

Particulars	Key management personnel and their relatives	Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries
<b>Sale of materials/services</b>		
Strides Pharma Sciences Limited		0.49
Strides Emerging Markets Limited		2.68
Solara Active Pharma Sciences Limited		38.80
Stelis Biopharma Private Limited		1.73
<b>Purchase of materials</b>		
Solara Active Pharma Sciences Limited		52.60
<b>Sale of assets</b>		
Mrs. Anita M Gupta	0.50	
<b>Managerial remuneration (*)</b>		
Mr. Manish Gupta	10.77	
Mr. Sharat Narsapur	5.13	
Mr. Tushar Mistry	4.79	
Mr. Krunal Shah	0.77	
<b>Directors Sitting Fees</b>		
Mr. K E C Rajakumar	0.10	
Mr. Narendra Mairpady	0.24	
Dr. S Devendra	0.20	
Dr. Kausalya Santhanam	0.24	
Dr. Gopakumar G. Nair	0.44	
<b>Reimbursement of expenses from</b>		
Solara Active Pharma Sciences Limited		0.25
Agnus Capital LLP		7.39
<b>Commission expense</b>		
Solara Active Pharma Sciences Limited		0.49
<b>Rent expense (**)</b>		
Solara Active Pharma Sciences Limited		4.20
Sequent Penems Private Limited		1.09

**C Balance as at 31 March 2020**

(₹ in Million)

<b>Trade Receivables / other current assets</b>		
Strides Pharma Sciences Limited		0.41
Strides Emerging Markets Limited		1.03
Solara Active Pharma Sciences Limited		8.55
Tenshi Kaizen Private Limited		- <sup>(A)</sup>
Stelis Biopharma Private Limited		1.22
Agnus Capital LLP		7.39
<b>Security deposit receivable</b>		
Solara Active Pharma Sciences Limited		4.20
Sequent Penems Private Limited		2.50
<b>Trade payables</b>		
Solara Active Pharma Sciences Limited		22.26
Sequent Penems Private Limited		0.39

(\*) Expenses towards gratuity and compensated absences provisions are determined actuarially on an overall company basis at the end of each year and accordingly have not been considered in the above information.

(\*\*) The rent expenses have been disclosed in financials statement as per Ind AS 116 - Leases.

(A) Not reported due to roundoff.



For Sequent Scientific Limited

*Tushar Mistry*  
Tushar Mistry  
Chief Financial Officer

*Krunal Shah*  
Krunal Shah  
Company Secretary